Mavacamten induces a clinical, hemodynamic, and biomarker response beyond the primary endpoint in EXPLORER-HCM: results from a post hoc machine learning analysis

临床终点 医学 析因分析 内科学 肥厚性心肌病 心脏病学 代理终结点 安慰剂 临床试验 终点测定 生物标志物 病理 生物化学 化学 替代医学
作者
Theodore P. Abraham,Amy J. Sehnert,W Anderson,Joshua Landis,W Li,G Kurio,Iacopo Olivotto
出处
期刊:European Heart Journal [Oxford University Press]
卷期号:43 (Supplement_2) 被引量:4
标识
DOI:10.1093/eurheartj/ehac544.1718
摘要

Abstract Introduction Mavacamten, a first-in-class selective inhibitor of cardiac myosin, was demonstrated in EXPLORER-HCM (NCT03470545) to be superior to placebo in achieving a primary endpoint of either (1) a ≥1.5 mL/kg/min increase in peak oxygen consumption (pVO2) and at least one New York Heart Association (NYHA) class reduction, or (2) a ≥3.0 mL/kg/min pVO2 increase without NYHA class worsening, in adults with obstructive hypertrophic cardiomyopathy (oHCM). However, the observed benefits of mavacamten were broader than the primary endpoint, suggesting a complex effect of the drug beyond improvements in these two parameters. Purpose A post hoc investigation of mavacamten clinical effects beyond the primary endpoint of EXPLORER-HCM. Methods EXPLORER data at week 30 were analyzed to evaluate improvements from baseline in primary (specified above), secondary (e.g. postexercise left ventricular outflow tract gradient and Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score) and exploratory endpoints (e.g. circulating NT-ProBNP and cardiac Troponin I). Responses were classified as improved or not improved based on published thresholds, clinical standards and analyses of the EXPLORER data. Patients were grouped according to their improvement status using unsupervised hierarchical clustering. Results The cluster analysis resulted in four main groups with the following trends (Table); Group 1 = patients who met the primary endpoint and showed improvement in secondary/exploratory endpoints; Group 2 = patients with improvement in secondary/exploratory endpoints who did not meet the primary endpoint; Group 3 = patients who met the primary endpoint without substantial secondary/exploratory endpoint responses; Group 4 = patients without appreciable improvement in any endpoint. A substantially larger proportion of patients in Group 1 received mavacamten compared with placebo (88% vs. 12%, respectively). A similar trend was observed in Group 2 patients who exhibited improvements in secondary/exploratory endpoints (85% mavacamten vs. 15% placebo). Group 3 consisted predominantly of placebo-treated patients who met the primary endpoint but had negligible responses to secondary/exploratory endpoints (5% mavacamten vs. 95% placebo). Group 4 consisted predominantly of placebo-treated patients without appreciable clinically relevant responses from this analysis (10% mavacamten vs. 90% placebo). Conclusions Mavacamten was associated with clinical improvements beyond the primary endpoint of EXPLORER-HCM and was predominantly accompanied by amelioration of other measures associated with oHCM pathophysiology. In contrast, most placebo-treated patients who met the primary endpoint did not exhibit improvement in the underlying pathophysiology. These findings suggest a potential underestimation of mavacamten clinical impact based on the primary endpoint and prompt a deeper examination of mavacamten efficacy in patients with oHCM based on other clinically relevant endpoints. Funding Acknowledgement Type of funding sources: Private company. Main funding source(s): MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
Jasper的应助被oo采纳,获得30
1秒前
英姑的应助被辰侑依采纳,获得10
1秒前
我我发布了新的文献求助10
1秒前
1秒前
2秒前
天天发布了新的文献求助10
2秒前
Owen的应助被温凛采纳,获得10
2秒前
强强发布了新的文献求助10
3秒前
3秒前
3秒前
袁rrrr完成签到,获得积分10
3秒前
ww完成签到,获得积分10
3秒前
3秒前
AAA麻精批发完成签到,获得积分10
4秒前
5秒前
巴拉巴拉发布了新的文献求助10
6秒前
111发布了新的文献求助30
6秒前
6秒前
悦耳的城发布了新的文献求助10
7秒前
花青素ii发布了新的文献求助10
7秒前
英姑的应助被李峥采纳,获得10
8秒前
kychao完成签到,获得积分10
9秒前
liugm发布了新的文献求助10
9秒前
9秒前
幻文悠发布了新的文献求助10
9秒前
英俊的铭的应助被快乐的忆安采纳,获得20
9秒前
找回自己发布了新的文献求助10
10秒前
10秒前
科研通AI2S的应助被yxxxxx采纳,获得10
11秒前
秋风的应助被仁爱的沁采纳,获得100
11秒前
斯文败类的应助被我我采纳,获得30
11秒前
顾矜的应助被SHN采纳,获得20
11秒前
羊村黑恶势力完成签到 ,获得积分10
12秒前
13秒前
小椿发布了新的文献求助10
13秒前
呼呼发布了新的文献求助10
14秒前
Selene发布了新的文献求助10
15秒前
小平头啤酒肚完成签到,获得积分10
15秒前
旦皋完成签到 ,获得积分10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193684
求助须知:如何正确求助?哪些是违规求助? 9579855
关于积分的说明 21867890
捐赠科研通 7793357
什么是DOI,文献DOI怎么找? 3437385
关于科研通互助平台的介绍 2560783
邀请新用户注册赠送积分活动 2484193